Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Boehringer Ingelheim
Baxter
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR DECADERM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Decaderm

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002798 ↗ Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1996-08-01 Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00016302 ↗ Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) N/A 2001-04-01 Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. This phase II trial is studying several different combination chemotherapy regimens to see how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia
NCT00022737 ↗ Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2002-10-01 This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
NCT00026234 ↗ Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed NSABP Foundation Inc Phase 2 2002-02-01 Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations and different ways may kill more tumor cells.
NCT00026234 ↗ Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed National Cancer Institute (NCI) Phase 2 2002-02-01 Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations and different ways may kill more tumor cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Decaderm

Condition Name

Condition Name for Decaderm
Intervention Trials
Stage II Multiple Myeloma 11
Stage III Multiple Myeloma 11
Refractory Multiple Myeloma 11
Stage I Multiple Myeloma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Decaderm
Intervention Trials
Multiple Myeloma 23
Neoplasms, Plasma Cell 22
Precursor Cell Lymphoblastic Leukemia-Lymphoma 10
Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Decaderm

Trials by Country

Trials by Country for Decaderm
Location Trials
United States 140
Canada 10
Australia 1
Switzerland 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Decaderm
Location Trials
California 14
Minnesota 11
Washington 9
Arizona 7
Ohio 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Decaderm

Clinical Trial Phase

Clinical Trial Phase for Decaderm
Clinical Trial Phase Trials
Phase 3 5
Phase 2 21
Phase 1/Phase 2 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Decaderm
Clinical Trial Phase Trials
Completed 22
Terminated 9
Active, not recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Decaderm

Sponsor Name

Sponsor Name for Decaderm
Sponsor Trials
National Cancer Institute (NCI) 33
Mayo Clinic 7
University of Washington 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Decaderm
Sponsor Trials
Other 39
NIH 33
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Colorcon
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.